Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000041475
JPRN-UMIN000041475
Completed
未知

Rituximab on Adult-onset frequenTly rElApsing or steroid dependent nephrotic syndrome study - A-TEAM study

Osaka University Graduate School of Medicine0 sites72 target enrollmentOctober 1, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsadult-onset frequently relapsing or steroid dependent nephrotic syndrome

Overview

Phase
未知
Intervention
Not specified
Conditions
adult-onset frequently relapsing or steroid dependent nephrotic syndrome
Sponsor
Osaka University Graduate School of Medicine
Enrollment
72
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2020
End Date
August 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. Patients with secondary nephrotic syndrome (including suspicion) 2\. Patients who have been treated with rituximab 3\.Patients with eGFR of 44mL / min / 1\.73m2 or less 4\.Patients with an infectious disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 3
IDEC-C2B8 clinical phase III trialAdult-onset frequently relapsing or steroid dependent nephrotic syndromenephrotic syndrome
JPRN-jRCT2051200045Isaka Yoshitaka64
Active, not recruiting
Phase 1
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM)and Adult Polmyositis (PM) - Rituximab in myositis (RIM)Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis.MedDRA version: 9.1Level: LLTClassification code 10036102Term: Polymyositis
EUCTR2006-000078-65-CZKarolinska University Hospital202
Active, not recruiting
Phase 1
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - Rituximab in myositisAdult polymyositis or adult dermatomyositis or juvenile dermatomyositisMedDRA version: 8.1Level: LLTClassification code 10036102Term: Polymyositis
EUCTR2006-000078-65-GBKarolinska University Hospital202
Active, not recruiting
Not Applicable
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - Rituximab in myositisAdult polymyositis or adult dermatomyositis or juvenile dermatomyositisMedDRA version: 8.1Level: LLTClassification code 10036102Term: Polymyositis
EUCTR2006-000078-65-SEKarolinska University Hospital202
Completed
Phase 2
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic LeukemiaMulticenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before ChemotherapyC85.1C91.0B-cell lymphoma, unspecifiedAcute lymphoblastic leukaemia [ALL]
DRKS00000908niversitäts-KinderklinikPädiatrische Hämatologie und Onkologie90